. The market has seen significant growth over the past few years and is predicted to grow significantly during the forecasted period as well.
CRISPR technology continues to make significant advances in genetic research and medicine in 2023, including recent breakthroughs like developing CRISPR-based therapies for genetic conditions such as sickle cell anemia and beta-thalassemia; clinical trials are advancing toward commercial release.
CRISPR technology, derived from bacteria, transforms biotechnology by precisely modifying DNA. Originally a defense mechanism in bacteria against viruses, it now allows scientists to quickly & accurately edit the DNA of plants, animals, & microorganisms.
Anticipated significant growth in the Global CRISPR Technology Market is driven by its large use in
healthcare, agriculture, & industry. Strong research initiatives & investments, both public and private, showcase the broad applications of CRISPR, ranging from organism engineering to crop modifications, gene therapies, & drug discoveries.
Agriculture is also taking advantage of CRISPR technology for crop enhancement and livestock breeding, as evidenced by its adoption by major agricultural biotechnology firms in April 2023 when one launched CRISPR-edited wheat with disease resistance - signaling increased market interest in gene-edited crops as an effective means to ensuring food security.
As regulatory frameworks continue to adapt, global governments are setting out clear guidelines for CRISPR applications in medicine, agriculture and industry. This regulatory progress could spur market expansion by making CRISPR technologies more readily accessible and commercially viable across various sectors.
CRISPR Technology Market presents many promising prospects in gene editing therapies for rare genetic diseases. Furthermore, its increased use in agriculture and biotechnology offers new avenues, with long-term growth prospects for genetically modified plants and livestock increasing dramatically each year.
As per sci-tech-today There is significant interest in CRISPR-based therapies, driven by the promising outcomes of ongoing clinical trials. More than 100 trials are currently taking place globally, targeting various genetic conditions and diseases. These trials are fueling excitement about CRISPR's potential to revolutionize genetic medicine in the near future.
Since its introduction, CRISPR technology has captivated the commercial and research sectors, leading to the registration of over 1,000 patents globally. At the same time, there is growing focus on the ethical and policy issues surrounding CRISPR, with about 50 countries introducing regulations to address these concerns and ensure responsible development.
Investments in CRISPR are on the rise, reaching billions of dollars, primarily fueled by funding from public agencies, biotech companies, and venture capitalists. Leading nations such as the U.S., China, and the U.K. are accelerating their efforts to advance CRISPR technology. Furthermore, the efficiency of CRISPR continues to improve, with usage precision now ranging from 50% to 90% depending on the experiment.
Market Dynamic
The global CRISPR technology market is expanding significantly due to the growth in the adoption of CRISPR worldwide, with revolutionary technology facilitating gene editing by transforming DNA from harmful variants to healthy ones, potentially preventing or curing genetic diseases. Further, the technological development in CRISPR is anticipated to be a key driver for the market's growth, enhancing its capabilities and applications.
However, the high costs associated with CRISPR create a challenge to the market's expansion. The potential prohibitive expense of CRISPR medicines for large patient groups raises accessibility concerns. In addition, ethical considerations in genetic research, mainly when conducted on populations with less average income & literacy levels, are expected to hinder market growth.
Addressing these ethical concerns is critical as highlighted by discussions from the National Human Genome Research Institute, to make sure responsible & equitable progress in genome editing technologies.
Research Scope and Analysis
By Product
The CRISPR technology market, categorized by product, encompasses Enzymes, Kits & Reagents, Guide RNA, and Others, among which the Enzymes Segment takes the lead in 2023 & is projected to maintain its dominance throughout the forecasted period, which is primarily driven by the growth in the demand & broad adoption of CRISPR technology. Cas9 enzymes, integral to the CRISPR-Cas9 technology, play an important role in gene editing applications, forming the foundation for the innovative & transformative capabilities of this technology.
Moreover, the Kits & Reagents Segment is expected to significantly grow in the coming years, driven by the growing research in gene editing tools, mainly designed to highlight the comprehensive spectrum of gene editing products within the CRISPR/Cas reaction, these kits are providing to the better understanding of CRISPR technology. The use of revolutionary CRISPR-Cas technology in these kits facilitates an innovative educational approach, enriching knowledge & awareness about this potent genetic tool.
By Application
The biomedical applications segment takes the lead in market dominance in 2023, driven by the broader adoption of CRISPR gene-editing technologies across different fields within the biological sciences, with the growth in utilization has highly contributed to higher revenue for this segment, with enhanced delivery methods & the introduction of nanocarriers enhancing the efficiency & specificity of CRISPR technology.
The major rise in studies & publications using this method for genome modification in human somatic cells & induced pluripotent stem cells further underscores its growing prominence, as few companies also provide commercial kits & services to support researchers engaged in this domain, supporting broader access to CRISPR applications in biomedical research.
Moreover, the
agricultural segment is anticipated for the fastest growth in the forecast period. The integration of innovative breeding technology has highly impacted agricultural production, as well as global access to nutrition-rich foods, which highlights the essential role CRISPR technology plays in developing agricultural practices & contributing to enhanced food security on a global scale.
By End User
The global CRISPR Technology market is significantly driven by the dominance of
biotechnology & pharmaceutical companies, which not only lead the market but also emerge as the fastest-growing segment throughout the forecast period, which is mainly driven by the strategic usage of advanced technologies by pharmaceutical companies to quickly identify & validate new therapeutic targets. In addition, these companies use such technologies to build more effective biological models for studying human diseases, reducing the time required for research and development.
Also, the increase of the market is expected to further accelerate owing to the increasing adoption of gene modification techniques by a rise in the number of biotechnology companies, both for research & commercial applications.
The increase in demand for CRISPR-based gene-editing methods, mainly in the development of innovative medicines like cell & gene therapies, highlights the important role played by CRISPR technology, with the continuous evolution of CRISPR's core architecture, extending its influence into the epigenome, improving control over epigenetic inheritance, further expanding its applications & relevance in the biotechnology & pharmaceutical landscape.
The CRISPR Technology Market Report is segmented on the basis of the following:
By Product
- Enzymes
- Kits & Reagents
- Guide RNA
- Others
By Application
- Biomedical
- Agricultural
- Others
By End User
- Biotechnology & Pharmaceutical Companies
- Academics & Government Research Institutes
- CROs
Regional Analysis
North America showcased its dominance in the market, claiming the highest revenue
share at 39.6% in 2023, which is due to the region's flourishing biopharmaceutical Research and development (R&D) sector, with various pharmaceutical corporations actively contributing to the creation of innovative therapeutics, thereby expanding the overall growth of the market.
Also, the Asia Pacific region is expected to have a rapid expansion throughout the forecast period, which is fueled by increased government investments in R&D initiatives focused on developing groundbreaking treatments.
Further, Japan & China play major roles in driving the region's growth, with China's expanded involvement anticipated to be a significant driver of the market. Moreover, combined efforts in these areas signify a promising trajectory for the Asia Pacific market, positioning it for significant development in the coming years.
By Region
North America
Europe
- Germany
- The U.K.
- France
- Italy
- Russia
- Spain
- Benelux
- Nordic
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- ANZ
- ASEAN
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Egypt
- Rest of MEA
Competitive Landscape
The CRISPR technology market experiences intense competition among major players, as the companies look for strategies like product developments, and expansions into different regions. Companies are also actively engaging in these measures to stay competitive & advance the market. These initiatives not only allow innovation but also enhance the accessibility & application of CRISPR technology, contributing to its overall development & expansion.
In September 2022, Vertex & CRISPR Therapeutics unveiled their discussions with the US Food and Drug Administration regarding the submission of exa-cel, scheduled for November 2022. Further companies anticipated completing the submission process by the end of the first quarter of 2023, which highlights their commitment to advancing medical innovations, bringing exa-cel to market, and addressing critical healthcare needs.
Some of the prominent players in the global CRISPR Technology Market are:
- Merck & Co
- Lonza
- GenScript
- Thermo Fisher Scientific
- Cellecta Inc
- New England Biolabs
- Vertex
- Cibus
- Danaher
- eGenesis
- Other Key Players
COVID-19 Pandemic & Recession: Impact on the Global CRISPR Technology Market:
The COVID-19 pandemic & the following economic recession have significantly impacted the global CRISPR technology market. While the pandemic highlighted the importance of advanced genetic research for understanding & combating viruses, it also led to interruptions in supply chains & research activities, impacting the market's growth. Despite these challenges, the pandemic increased the adoption of CRISPR technologies in vaccine development & therapeutic research.
The economic recession created financial constraints on research budgets, impacting investment in CRISPR-related projects. However, as the world looks through recovery, the CRISPR technology market is anticipated to rebound, driven by a renewed focus on healthcare innovation & an increase in realization of the major role CRISPR can play in addressing global health challenges.
| Report Characteristics |
| Market Size (2023) |
USD 3.2 Bn |
| Forecast Value (2032) |
USD 14.0 Bn |
| CAGR (2023-2032) |
17.8% |
| Historical Data |
2017 - 2022 |
| Forecast Data |
2023 - 2032 |
| Base Year |
2022 |
| Estimate Year |
2023 |
| Report Coverage |
Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors and etc. |
| Segments Covered |
By Product (Enzymes, Kits & Reagents, Guide RNA,
and Others), By Application (Biomedical, Agricultural,
and Others), By End User (Biotechnology &
Pharmaceutical Companies, Academics &
Government Research Institutes, and CROs) |
| Regional Coverage |
North America – The US and Canada; Europe – Germany, The UK, France, Russia, Spain, Italy, Benelux, Nordic, & Rest of Europe; Asia- Pacific– China, Japan, South Korea, India, ANZ, ASEAN, Rest of APAC; Latin America – Brazil, Mexico, Argentina, Colombia, Rest of Latin America; Middle East & Africa – Saudi Arabia, UAE, South Africa, Turkey, Egypt, Israel, & Rest of MEA
|
| Prominent Players |
Merck & Co, Lonza, GenScript, Thermo Fisher
Scientific, Cellecta Inc, New England Biolabs, Vertex,
Cibus, Danaher, eGenesis, and Other Key Players |
| Purchase Options |
We have three licenses to opt for: Single User License (Limited to 1 user), Multi-User License (Up to 5 Users), and Corporate Use License (Unlimited User) along with free report customization equivalent to 0 analyst working days, 3 analysts working days and 5 analysts working days respectively. |